Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2014-01-15 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Senior managers’ and Directors’ subscriptions in new issue
Share Issue/Capital Change Classification · 1% confidence The document is a 'NEWS RELEASE' dated January 15, 2014, with the headline 'Senior managers' and Directors' subscriptions in new issue'. The content details specific commitments by the Chairman of the Board, CEO, COO, and other directors/researchers to subscribe to shares in the company's current rights issue. This directly relates to insider transactions concerning the company's capital structure and share ownership changes involving management/directors. While it mentions a 'rights issue' (related to CAP), the core focus is reporting the personal subscription intentions of directors and senior managers. This aligns most closely with 'Director's Dealing' (DIRS) or potentially 'Share Issue/Capital Change' (SHA). However, since the primary subject is the *action* taken by directors/managers regarding subscribing to new shares, DIRS (Report of personal share transactions by company directors and executives) is a strong fit, as these subscriptions are personal transactions by insiders. Given the context of reporting insider participation in a capital event, DIRS is the most specific classification for this type of disclosure.
2014-01-15 English
Teckning i nyemission av ledande befattningshavare och styrelseledamöter
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated 2014-01-15 announcing that members of the board and senior management intend to subscribe (teckning) in an ongoing rights issue (förtesemission). This action relates directly to the company's capital structure and financing activities, specifically involving insiders subscribing to new shares. This aligns best with the 'Capital/Financing Update' category (CAP), as it details participation in a fundraising effort. It is not a general regulatory filing (RNS) because it is highly specific to a financing event, nor is it a Director's Dealing report (DIRS) which typically reports completed personal transactions, but rather an announcement of intent to subscribe in a corporate offering.
2014-01-15 Swedish
NeuroVive Pharmaceutical AB (publ) publishes prospectus
Share Issue/Capital Change Classification · 1% confidence The document is titled "NEWS RELEASE" and explicitly states, "NeuroVive Pharmaceutical AB (publ) publishes prospectus." It details a rights issue (a capital/financing activity) and announces that the prospectus related to this issue has been approved and registered. The text provides key financial figures included in the prospectus and directs readers to download the prospectus and application forms. Since the document's primary function is to announce the publication of a formal document (the prospectus) related to a capital change (rights issue), it fits the definition of a Report Publication Announcement (RPA) or, given the context of a rights issue, potentially a Capital/Financing Update (CAP). However, the core action described is the *publication* of the prospectus, which is a formal announcement of a report/document release. Given the options, RPA is the most precise fit for announcing the availability of a formal document like a prospectus, especially since the document itself is a short news release summarizing the event rather than the full prospectus or a general financing update. The document length (5035 chars) is moderate, but the content focuses heavily on the release of the prospectus. I will classify this as RPA because the headline is about publishing the prospectus, and the body directs users to download it, aligning with the RPA definition: "Announcement regarding the timing, release, or publication of company reports."
2014-01-08 English
NeuroVive Pharmaceutical AB (publ) offentliggör prospekt
Capital/Financing Update Classification · 1% confidence The document is a press release dated 2014-01-08 announcing that NeuroVive Pharmaceutical AB has published a prospectus ('offentliggör prospekt') related to a rights issue ('nyemission'). It details the expected proceeds, provides previously unpublished financial data (equity, debt, cash as of Nov 30, 2013, and Jan 8, 2014), and gives instructions on how to obtain the prospectus and the timeline for the rights issue. Since the core action is the publication of a prospectus related to a financing activity (a rights issue), this falls under 'Capital/Financing Update' (CAP). Although it announces a document (the prospectus), the primary focus and content are the details of the capital raise itself, making CAP more specific than RPA or RNS. The prospectus itself would likely be classified under CAP or potentially LTR/IP depending on its content, but this announcement is about the financing event.
2014-01-08 Swedish
Riktad nyemission i NeuroVive på 35 MSEK genomförd och mer information om kommande företrädesemission på 75,8 MSEK
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and details two key financial/corporate actions: the completion of a directed share issue (riktad nyemission) raising 35 MSEK, and the announcement of an upcoming rights issue (förtädesemission) to raise approximately 75.8 MSEK. It also mentions the launch of an IR portal and schedules investor meetings related to the upcoming financing. This content strongly indicates an announcement related to capital raising and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full 10-K, an Earnings Release (ER) which focuses on operational results, or a simple Report Publication Announcement (RPA) as it contains substantive news about the financing itself, not just the publication of a separate report.
2013-12-18 Swedish
NeuroVive—SEK 35 m private placement complete, more information on forthcoming SEK 75.8 m rights issue
Share Issue/Capital Change Classification · 1% confidence The document is a 'NEWS RELEASE' dated December 18, 2013, announcing the completion of a SEK 35 million private placement and providing details about a forthcoming SEK 75.8 million rights issue, including subscription periods and planned investor events. This content directly relates to fundraising, capital structure changes, and shareholder entitlement regarding new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). Although it mentions an EGM approval, the primary focus is the financing activity itself, not the voting results (DVA) or the AGM materials (AGM-R). It is not a full annual report (10-K) or an interim report (IR).
2013-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.